Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209598 · ClinicalTrials.gov registry record · Phase 2
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01209598: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01209598 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209598, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects, good and/or bad, Palbociclib (Ibrance) (formerly known as PD0332991) has on the patient and on the liposarcoma. Palbociclib is an investigational drug. An investigational drug is a medication that has not been approved for marketing by the Food and Drug Administration (FDA). Palbociclib blocks a protein called CDK4 which is part of a pathway in liposarcoma cells that is over-active. The investigators hope that blocking CDK4 will shut down this pathway in the liposarcoma cells and stop tumors from growing. Palbociclib is an oral medication.
Interventions
- DRUG Palbociclib 125mg
- DRUG Palbociclib 200mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-09-23 |
| Est. Completion | 2016-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209598
The ClinicalTrials.gov registry entry for NCT01209598 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib 125mg is the first listed.
NCT01209598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209598 about?
NCT01209598 is a clinical study titled "PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma". The purpose of this study is to find out what effects, good and/or bad, Palbociclib (Ibrance) (formerly known as PD0332991) has on the patient and on the liposarcoma. Palbociclib is an investigational drug. An investigational drug is a medication that has not been approved for marketing by the Food...
What is the current status of trial NCT01209598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2010-09-23. Estimated completion is 2016-10-25.
What interventions are being tested in trial NCT01209598?
The interventions under investigation include: Palbociclib 125mg (DRUG), Palbociclib 200mg (DRUG).
Who is sponsoring clinical trial NCT01209598?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.